Intensity Therapeutics

INTS · NASDAQ

$3.28−$0.01 (−0.30%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.29

INTS analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $17.54 (+434.9% upside)

Low: $7.07
Now: $3.28
High: $33.60

Upgrades and downgrades

The latest rating actions, newest first

INTS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Aug 18, 2026	Maintains	Buy	$5.00 → $7.00	43%

The case for and against

Updated Apr 17, 2025

Bull case

Intensity Therapeutics Inc. is projected to achieve risk-adjusted total product revenues of approximately $1.1 million in 2027, with a substantial growth anticipated to $181.7 million by 2031, reflecting an impressive compound annual growth rate (CAGR) of 89%. The encouraging immunological responses evidenced by significant increases in CD4+ and CD8+ T-cells following INT230-6 treatment, along with the potential for abscopal effects on non-injected tumor lesions, highlight the therapeutic efficacy and broad applicability of its innovative drug. Additionally, various factors such as earlier market approvals, better commercialization than expected, and a potentially expansive proprietary pipeline could enhance revenue projections, further supporting a positive outlook for the company's stock.

Bear case

Intensity Therapeutics reported a significant net loss of $5.0 million, translating to a loss of $0.36 per diluted share in the second quarter of 2024, indicating challenges in attaining financial stability. The company's revenue projections face uncertainty due to potential difficulties in product commercialization, market penetration, and obtaining critical regulatory approvals, which could hinder its ability to generate revenue. Furthermore, clinical trial delays and patient enrollment issues may adversely affect the timely completion of clinical trials and regulatory processes, heightening the risks associated with investing in the company’s stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.